In this two-institutional study, longitudinal information from clinical data and radiomics was used to predict clinical durable benefit at 6 and 9 months after the start of anti-PD-1/PD-L1 monoclonal antibodies treatment in advanced NSCLC patients using an ensemble approach. The gene discussed is CD274; the disease is non-small cell lung carcinoma.